PC-1/PrLZ contributes to malignant progression in prostate cancer

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8906-8913

  Zhang, Hui ^a   Wang, Jian ^a   Pang, Bo ^a   Liang, Rui Xia ^a   Li, Suping ^a   Huang, Pei Tang ^a   Wang, Ruoxiang ^b   Chung, Leland W K ^b   Zhau, Haiyen E ^b   Huang, Cuifen ^a   Zhou, Jian Guang ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; PROTEIN KINASE B;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER GROWTH; CARCINOGENICITY; CELL STRAIN 3T3; CELL STRAIN LNCAP; COLONY FORMATION; CONTROLLED STUDY; DNA VECTOR; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUDE MOUSE; PC 1 GENE; PHENOTYPE; PRIORITY JOURNAL; PRLZ GENE; PROSTATE CANCER; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA, ANTISENSE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NIH 3T3 CELLS; NITRILES; ONCOGENE PROTEIN V-AKT; PHOSPHORIC DIESTER HYDROLASES; PROSTATIC NEOPLASMS; PYROPHOSPHATASES; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; TRANSFECTION;

EID: 34548782263     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4214     Document Type: Article

References (44)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
2. Zhau HY, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88:2995-3001.
3. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26:263-73.
4. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389-96.
5. Feldman BJ, Felman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43:1809-18.
7. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
8. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
9. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
10. Wang RX, Xu JC, Saramaki O, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004;64:1589-94.
11. Byrne JA, Tomasetto C, Garnier JM, et al. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995;55:2896-903.
12. Byrne JA, Mattei MG, Basset P. Definition of the tumor protein D52(TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996;35:523-32.
13. Chen SL, Maroulakou IG, Green JE, et al. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene 1996;12:741-51.
14. Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun 2004;325:1115-21.
15. Byrne JA, Nourse CR, Basset P, Gunning P. Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene 1998;16:873-81.
16. Sathasivam P, Bailey AM, Crossley M, Byrne JA. The role of the coiled-coil motif in interactions mediated by TPD52. Biochem Biophys Res Commun 2001;288:56-61.
17. Wilson SH, Bailey AM, Nourse CR, Mattei MG, Byrne JA. Identification of MAL2, a novel member of the MAL proteolipid family, through interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics 2001; 76:81-8.
18. 2+-sensitive CRHSP-28-binding protein in pancreatic acinar cells. J Biol Chem 2002; 277:35496-502.
19. Proux-Gillardeaux V, Galli T, Callebaut I, Mikhailik A, Calothy G, Marx M. D53 is a novel endosomal SNARE-binding protein that enhances interaction of syntaxin 1 with the Synaptobrevin 2 complex in vitro. Biochem J 2003;370:213-21.
20. Boutros R, Bailey AM, Wilson SH, Byrne JA. Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. J Mol Biol 2003;332:675-87.
21. Cho S, Ko HM, Kim JM, et al. Positive regulation of apoptosis signal-regulating kinase 1 by hD53L1. J Biol Chem 2004;279:16050-6.
22. Pandini G, Mineo R, Frasca F, et al. Androgens upregulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005;65:1849-57.
23. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18:2755-61.
24. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 2002;21:5069-80.
25. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. ErbB1and prostate cancer: ErbB1activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003;56:142-9.
26. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 2006;281:29938-48.
27. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
28. Chang XT, Liang RX, Zhou JG, et al. Malignant transformation of NIH3T3 cells induced by ectopic expression of PC-1 gene. Zhonghua Bing Li Xue Za Zhi (Chin J Pathol) 2005;34:42-6.
29. Zhang H, Wan LC, Wang J, Zhou JG, Huang CF. Effect of PC-1 expression on migration ability of prostate cancer cells. Ai Zheng (Chin J Cancer) 2005;24:1043-7.
30. Passaniti A, Isaacs JT, Haney JA, et al. Stimulation of human prostatic carcinoma tumor growth in athymic nude mice and control of migration in culture by extracellular matrix. Int J Cancer 1992;51:318-24.
31. Li S, Ferber A, Miura M, Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem 1994;269:32558-64.
32. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
33. Dolloff NG, Shulby SS, Nelson AV, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by a platelet-derived growth factor receptor. Oncogene 2005;24:6848-54.
34. Lu S, Ren C, Liu Y, Epner DE. PI3K-Akt signaling is involved in the regulation of p21WAF/CIP expression and androgen-independent growth in prostate cancer cells. Int J Oncol 2006;28:245-51.
35. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141:2257-65.
36. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
37. Nakatani K, Thompson DA, Barthel A, et al. Upregulation of Akt3 in estrogen receptordeficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
38. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone resistant prostate cancer. Clin Cancer Res 2003;9:5271-81.
39. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non neoplastic tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-8.
40. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003;100:7841-6.
41. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51.
42. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3h in cellular signaling. Prog Neurobiol 2001;65:391-426.
43. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-4.
44. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.